265 related articles for article (PubMed ID: 16778093)
21. Molecular cancer therapy: can our expectation be MET?
Migliore C; Giordano S
Eur J Cancer; 2008 Mar; 44(5):641-51. PubMed ID: 18295476
[TBL] [Abstract][Full Text] [Related]
22. Mechanisms of hepatocyte growth factor-induced retinal endothelial cell migration and growth.
Cai W; Rook SL; Jiang ZY; Takahara N; Aiello LP
Invest Ophthalmol Vis Sci; 2000 Jun; 41(7):1885-93. PubMed ID: 10845613
[TBL] [Abstract][Full Text] [Related]
23. Tyrosine phosphorylation of p145met mediated by EGFR and Src is required for serum-independent survival of human bladder carcinoma cells.
Yamamoto N; Mammadova G; Song RX; Fukami Y; Sato K
J Cell Sci; 2006 Nov; 119(Pt 22):4623-33. PubMed ID: 17062641
[TBL] [Abstract][Full Text] [Related]
24. EMD 1214063 and EMD 1204831 constitute a new class of potent and highly selective c-Met inhibitors.
Bladt F; Faden B; Friese-Hamim M; Knuehl C; Wilm C; Fittschen C; Grädler U; Meyring M; Dorsch D; Jaehrling F; Pehl U; Stieber F; Schadt O; Blaukat A
Clin Cancer Res; 2013 Jun; 19(11):2941-51. PubMed ID: 23553846
[TBL] [Abstract][Full Text] [Related]
25. Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer.
De Bacco F; Luraghi P; Medico E; Reato G; Girolami F; Perera T; Gabriele P; Comoglio PM; Boccaccio C
J Natl Cancer Inst; 2011 Apr; 103(8):645-61. PubMed ID: 21464397
[TBL] [Abstract][Full Text] [Related]
26. Hepatocyte growth factor and Met in tumor biology and therapeutic approach with NK4.
Matsumoto K; Nakamura T; Sakai K; Nakamura T
Proteomics; 2008 Aug; 8(16):3360-70. PubMed ID: 18646008
[TBL] [Abstract][Full Text] [Related]
27. Structure, biosynthesis and biochemical properties of the HGF receptor in normal and malignant cells.
Comoglio PM
EXS; 1993; 65():131-65. PubMed ID: 8380735
[TBL] [Abstract][Full Text] [Related]
28. Hepatocyte growth factor and its receptor, the tyrosine kinase encoded by the c-MET proto-oncogene.
Vigna E; Naldini L; Tamagnone L; Longati P; Bardelli A; Maina F; Ponzetto C; Comoglio PM
Cell Mol Biol (Noisy-le-grand); 1994 Jul; 40(5):597-604. PubMed ID: 7981617
[TBL] [Abstract][Full Text] [Related]
29. Osthole suppresses hepatocyte growth factor (HGF)-induced epithelial-mesenchymal transition via repression of the c-Met/Akt/mTOR pathway in human breast cancer cells.
Hung CM; Kuo DH; Chou CH; Su YC; Ho CT; Way TD
J Agric Food Chem; 2011 Sep; 59(17):9683-90. PubMed ID: 21806057
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
Qian F; Engst S; Yamaguchi K; Yu P; Won KA; Mock L; Lou T; Tan J; Li C; Tam D; Lougheed J; Yakes FM; Bentzien F; Xu W; Zaks T; Wooster R; Greshock J; Joly AH
Cancer Res; 2009 Oct; 69(20):8009-16. PubMed ID: 19808973
[TBL] [Abstract][Full Text] [Related]
31. Single-agent and combination therapeutic strategies to inhibit hepatocyte growth factor/MET signaling in cancer.
Toschi L; Jänne PA
Clin Cancer Res; 2008 Oct; 14(19):5941-6. PubMed ID: 18829470
[TBL] [Abstract][Full Text] [Related]
32. Overexpression of c-met in oral SCC promotes hepatocyte growth factor-induced disruption of cadherin junctions and invasion.
Murai M; Shen X; Huang L; Carpenter WM; Lin CS; Silverman S; Regezi J; Kramer RH
Int J Oncol; 2004 Oct; 25(4):831-40. PubMed ID: 15375530
[TBL] [Abstract][Full Text] [Related]
33. Hepatocyte growth factor induces Wnt-independent nuclear translocation of beta-catenin after Met-beta-catenin dissociation in hepatocytes.
Monga SP; Mars WM; Pediaditakis P; Bell A; Mulé K; Bowen WC; Wang X; Zarnegar R; Michalopoulos GK
Cancer Res; 2002 Apr; 62(7):2064-71. PubMed ID: 11929826
[TBL] [Abstract][Full Text] [Related]
34. MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor.
Pan BS; Chan GK; Chenard M; Chi A; Davis LJ; Deshmukh SV; Gibbs JB; Gil S; Hang G; Hatch H; Jewell JP; Kariv I; Katz JD; Kunii K; Lu W; Lutterbach BA; Paweletz CP; Qu X; Reilly JF; Szewczak AA; Zeng Q; Kohl NE; Dinsmore CJ
Cancer Res; 2010 Feb; 70(4):1524-33. PubMed ID: 20145145
[TBL] [Abstract][Full Text] [Related]
35. Hepatocyte growth factor stimulates cell motility in cultures of the striatal progenitor cells ST14A.
Cacci E; Salani M; Anastasi S; Perroteau I; Poiana G; Biagioni S; Augusti-Tocco G
J Neurosci Res; 2003 Dec; 74(5):760-8. PubMed ID: 14635227
[TBL] [Abstract][Full Text] [Related]
36. The Met receptor tyrosine kinase: a key player in oncogenesis and drug resistance.
Maroun CR; Rowlands T
Pharmacol Ther; 2014 Jun; 142(3):316-38. PubMed ID: 24384534
[TBL] [Abstract][Full Text] [Related]
37. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer.
Maulik G; Kijima T; Ma PC; Ghosh SK; Lin J; Shapiro GI; Schaefer E; Tibaldi E; Johnson BE; Salgia R
Clin Cancer Res; 2002 Feb; 8(2):620-7. PubMed ID: 11839685
[TBL] [Abstract][Full Text] [Related]
38. Met and hepatocyte growth factor/scatter factor signal transduction in normal melanocytes and melanoma cells.
Halaban R; Rubin JS; Funasaka Y; Cobb M; Boulton T; Faletto D; Rosen E; Chan A; Yoko K; White W
Oncogene; 1992 Nov; 7(11):2195-206. PubMed ID: 1331934
[TBL] [Abstract][Full Text] [Related]
39. The Hepatocyte Growth Factor Receptor: Structure, Function and Pharmacological Targeting in Cancer.
Cecchi F; Rabe DC; Bottaro DP
Curr Signal Transduct Ther; 2011; 6(2):146-151. PubMed ID: 25197268
[TBL] [Abstract][Full Text] [Related]
40. C-MET as a potential target therapy toward personalized therapy in some pediatric tumors: An overview.
Rashed WM
Crit Rev Oncol Hematol; 2018 Nov; 131():7-15. PubMed ID: 30293708
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
